Skip to main content
. Author manuscript; available in PMC: 2024 Mar 8.
Published in final edited form as: J Allergy Clin Immunol Pract. 2023 Oct 31;12(2):372–382.e2. doi: 10.1016/j.jaip.2023.10.044

TABLE VI.

Univariable analysis and multivariable model for mental components of general health—related QoL (SF-8 MC) in all subjects

Characteristics Univariable associations Final multivariable model
Median (IQR) P value Unstandardized β coefficient (95% CI) P value
Sex* <.001
 Female 50.0 (43.5–56.0) −2.4 (−3.5 to −1.3) <.001
 Male 53.9 (49.3–57.4) Reference
Age (y)* .447
 <35 52.1 (46.8–57.3)
 35–45 52.1 (47.1–57.5)
 ≥45 51.0 (43.0–57.5)
Smoking habit* .248
 Never smoked 52.1 (47.0–57.5)
 Ex-smoker 52.4 (46.1–57.5)
 Current smoker 51.3 (44.8–57.3)
Body mass index (kg/m2)* .279
 <25 52.3 (46.9–57.5)
 ≥25 51.3 (45.0–57.4)
Education level* .458
 >12 y 51.5 (46.7–57.3)
 ≤12 y 52.0 (46.3–57.5)
Current job duration* .047
 <5 y 52.3 (48.1–57.5)
 ≥5 y 51.4 (45.2–57.4)
Asthma preexisting to current job
 Yes 49.4 (42.1–54.8) .505
 No 49.6 (39.0–54.6)
Asthma control .016
 ACT score > 19 49.9 (42.9–55.0)
 ACT score ≤ 19 46.1 (40.3–51.6)
Asthma* <.001
 Absent 52.4 (48.2–57.5) Reference
 Non-WRA 50.7 (43.9–56.3) −2.1 (−3.7 to −0.5) .009
 WRA 45.7 (36.6–52.4) −4.6 (−6.5 to −2.7) <.001
Depression, physician-based <.001
 Absent 52.3 (48.1–57.5) Reference
 Present 43.7 (37.1–52.3) −7.6 (−9.3 to −5.8) <.001
Nonrespiratory, nondepression comorbidity .006
 Absent 52.5 (46.8–57.5) Reference
 Present 50.8 (45.6–56.6) −2.1 (−3.3 to −0.9) <.001

IQR, Interquartile range.

Multivariable analysis was done on 822 subjects and incorporated well-known confounders such as age, sex, smoking habits, body mass index, academic level, and current job duration (marked with asterisks) and other covariates with a P value of <.1 in univariable analyses. Asthma control was not included because the information was available only among asthmatic subjects.

*

Well-known confounders included in the multivariable analysis.

WRA is defined as current asthma associated with ≥2 WRA symptoms.